Perioral Dermatitis Treatment Guidelines

Introduction to Tacrolimus

• The American Academy of Dermatology acknowledges that tacrolimus does not cause skin atrophy, unlike topical corticosteroids 1
• A theoretical cancer risk exists with tacrolimus, though clinical evidence does not support a causal link, as noted by the FDA 2
• The American Academy of Dermatology and the Journal of Allergy and Clinical Immunology agree that tacrolimus is particularly effective for cases exacerbated by prior topical corticosteroid use, and topical corticosteroids should be avoided as they can exacerbate perioral dermatitis 1

Contraindications and Precautions

• The Journal of Allergy and Clinical Immunology recommends that tacrolimus is not recommended for children under 2 years 3
• Use caution in immunocompromised patients when prescribing tacrolimus, as advised by Praxis Medical Insights 4

Treatment Approach

• The American Academy of Dermatology suggests that topical corticosteroids should be avoided as they can exacerbate perioral dermatitis, and instead, tacrolimus 0.1% ointment can be applied twice daily for 2-4 weeks 1
• The evidence supporting tacrolimus for perioral dermatitis is moderate, with guidelines acknowledging calcineurin inhibitors as steroid-sparing agents for sensitive areas, as stated by the American Academy of Dermatology 1 and the Journal of the American Academy of Dermatology 2